Source: International Congress 2018 – Understanding the immunopathology that underlies airway obstructive diseases
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Wenzel (Pittsburgh, United States of America), I. Pavord (Oxford, United Kingdom), K. Rabe (Kiel, Germany), A. Papi (Ferrarra, Italy), J. Fitzgerald (Vancouver, Canada), A. Jagerschmidt (Chilly-Mazarin, France), W. Brian (Chilly-Mazarin, France), Q. Dong (Bridgewater, United States of America), B. Swanson (Bridgewater, United States of America), J. Hamilton (Tarrytown, United States of America), N. Amin (Tarrytown, United States of America), G. Pirozzi (Bridgewater, United States of America), M. Ruddy (Tarrytown, United States of America), B. Akinlade (Tarrytown, United States of America), N. H. Graham (Tarrytown, United States of America), A. Teper (Bridgewater, United States of America). Dupilumab shows rapid and sustained suppression of inflammatory biomarkers in asthma patients in LIBERTY ASTHMA QUEST. 5005

Member's Comments

No comment yet.

Related content which might interest you: Dupilumab shows rapid and sustained suppression of inflammatory biomarkers in corticosteroid (CS)-dependent severe asthma patients in LIBERTY ASTHMA VENTURE Source: International Congress 2018 – Understanding the immunopathology that underlies airway obstructive diseases Year: 2018 Impact of severe exacerbations on lung function in dupilumab-treated patients: LIBERTY ASTHMA QUEST Source: Virtual Congress 2021 – Pearls in immunology, outcome studies and clinical trials in asthma, alpha-1 antitrypsin deficiency and COPD Year: 2021 Efficacy of dupilumab in patients with oral corticosteroid (OCS)-dependent, severe asthma with and without an allergic phenotype: phase 3 LIBERTY ASTHMA VENTURE Source: Virtual Congress 2021 – Asthma and COPD meets COVID-19: new diagnostic tools and results from clinical trials Year: 2021 Dupilumab improves SNOT-22 scores in asthma patients with chronic rhinosinusitis or nasal polypsosis (CRS/NP) in LIBERTY ASTHMA QUEST Source: International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures Year: 2018 Dupilumab improves asthma-related patient reported outcomes in asthma patients with chronic rhinosinusitis or nasal polyposis (CRS/NP) in LIBERTY ASTHMA QUEST Source: International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures Year: 2018 Late Breaking Abstract - Dupilumab long-term safety and efficacy in patients with asthma: LIBERTY ASTHMA TRAVERSE Source: Virtual Congress 2020 – ALERT: Asthma in adults and children Year: 2020 Dupilumab efficacy in asthma patients with comorbid chronic rhinosinusitis or nasal polyposis (CRS/NP) in LIBERTY ASTHMA QUEST Source: International Congress 2018 – Novel immunology-based therapies in asthma and COPD Year: 2018 Serum GAL3 predict response in omalizumab-treated patients with severe allergic asthma: the PROXIMA study Source: International Congress 2018 – Innovative therapies in asthma and COPD Year: 2018 Eosinophilic phenotype classification of patients with asthma and/or COPD in NOVELTY Source: Virtual Congress 2021 – Biomarkers to phenotype asthma: prediction of exacerbations Year: 2021 Exacerbation burden in mild asthma: Evidence from the NOVELTY study Source: Virtual Congress 2020 – Prediction of outcomes in obstructive diseases Year: 2020 Comparison of spirometric markers of severity and reversibility in patients with asthma and/or COPD in NOVELTY Source: Virtual Congress 2020 – New tools for risk stratification of obstructive diseases Year: 2020 Dysinapsis in COPD and ASTHMA Source: Eur Respir J 2003; 22: Suppl. 45, 416s Year: 2003 The relationship between persistent systemic inflammation and symptoms of depression among patients with COPD in the ECLIPSE cohort Source: Annual Congress 2013 –The best abstracts in extra-pulmonary features and pulmonary rehabilitation Year: 2013 Factors associated with exacerbations in patients with COPD: NOVELTY study Source: Virtual Congress 2020 – COPD and the impact of comorbidities Year: 2020 Montelukast reduces viral-induced asthma exacerbations: the PREVIA study Source: Eur Respir J 2004; 24: Suppl. 48, 212s Year: 2004 Clinical factors associated with baseline blood eosinophils among patients with asthma or COPD: NOVELTY study Source: Virtual Congress 2020 – Burden and predictive factors for chronic lung diseases and comorbidity Year: 2020 Characteristics by physician-assigned severity of asthma, asthma+COPD and COPD patients in the NOVELTY study Source: International Congress 2019 – Clinical implications of asthma management Year: 2019 Completion of early pulmonary rehabilitation after COPD exacerbation reduces hospital admissionsSub-group analysis from the COPD-EXA-REHAB STUDY Source: International Congress 2019 – The future of pulmonary rehabilitation discussed today Year: 2019 EOSINOPHIL COUNT AND FeNO AS PREDICTORS OF EXACERBACTIONS IN COPD Source: International Congress 2018 – Clinical determinants and biomarkers of COPD Year: 2018 Mometasone/indacaterol/glycopyrronium (MF/IND/GLY) improves lung function and reduces exacerbations in patients with asthma, independent of baseline airflow limitation: Results from IRIDIUM study Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence Year: 2021